Literature DB >> 47148

Activation of the properdin pathway of complement in patients with gram-negative of bacteremia.

D T Fearon, S Ruddy, P H Schur, W R McCabe.   

Abstract

To determine the pathway used for activation of complement component C3, serum levels of components C1, C4, C2, C3, C5, C6, and C9 and two properdin factors, properdin and factor B, were measured in 42 patients with gram-negative bacteremia, in 19 of whom shock subsequently developed. Mean levels of the classical components C1, C4, and C2 in bacteremic patients in whom shock subsequently developed did not differ significantly (p greater than 0.05) from those of patients with uncomplicated bacteremia. Levels of properdin, factor B and C3, C5, C6, and C9 were significantly (p less than 0.05) decreased in patients with shock in comparison with those with uncomplicated bacteremia. Taken together, these findings are consistent with activation of C3 and the terminal complement sequence, C5-C9, occurring primarily by the properdin pathway, in patients with gram-negative bacteremia eventuating in shock. Biologically active products released during activation of C3-C9 may contribute to the development of shock.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 47148     DOI: 10.1056/NEJM197505012921802

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  60 in total

Review 1.  Review: assessment of complement activation in clinical immunology laboratories: time for reappraisal?

Authors:  M Peakman; G Senaldi; D Vergani
Journal:  J Clin Pathol       Date:  1989-10       Impact factor: 3.411

Review 2.  A model for the interplay of inflammatory mediators in sepsis--a study in 48 patients.

Authors:  C E Hack; J H Nuijens; R J Strack van Schijndel; J J Abbink; A J Eerenberg; L G Thijs
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

3.  Changes in humoral components of host defense following burn trauma.

Authors:  A B Bjornson; W A Altemeier; H S Bjornson
Journal:  Ann Surg       Date:  1977-07       Impact factor: 12.969

4.  Circulating complement proteins in patients with sepsis or systemic inflammatory response syndrome.

Authors:  S Stöve; T Welte; T O Wagner; A Kola; A Klos; W Bautsch; J Köhl
Journal:  Clin Diagn Lab Immunol       Date:  1996-03

5.  Magnitude of bacteremia and complement activation during Neisseria meningitidis infection: study of two co-primary cases with different clinical presentations.

Authors:  A Zwahlen; F A Waldvogel
Journal:  Eur J Clin Microbiol       Date:  1984-10       Impact factor: 3.267

6.  Complement activation in Staphylococcus aureus bacteraemia.

Authors:  A F Hallett; R Cooper
Journal:  Clin Exp Immunol       Date:  1980-05       Impact factor: 4.330

7.  Inherited deficiency of the second component of complement. Rheumatic disease associations.

Authors:  D Glass; D Raum; D Gibson; J S Stillman; P H Schur
Journal:  J Clin Invest       Date:  1976-10       Impact factor: 14.808

8.  Proteolytic inactivation of plasma C1- inhibitor in sepsis.

Authors:  J H Nuijens; A J Eerenberg-Belmer; C C Huijbregts; W O Schreuder; R J Felt-Bersma; J J Abbink; L G Thijs; C E Hack
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

9.  Selective activation of classical and alternative pathways of human complement by "promptly serum-sensitive" and "delayed serum-sensitive" strains of Serratia marcescens.

Authors:  W H Traub; I Kleber
Journal:  Infect Immun       Date:  1976-05       Impact factor: 3.441

10.  Consumptive opsoninopathy: possible pathogenesis in lethal and opportunistic infections.

Authors:  J W Alexander; M A McClellan; C K Ogle; J D Ogle
Journal:  Ann Surg       Date:  1976-12       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.